$4.90
2.51% day before yesterday
Nasdaq, Aug 22, 10:00 pm CET
ISIN
US52886X1072
Symbol
LXEO

Lexeo Therapeutics Stock price

$4.90
+1.01 25.96% 1M
+1.17 31.37% 6M
-1.68 25.53% YTD
-7.28 59.77% 1Y
-6.10 55.45% 3Y
-6.10 55.45% 5Y
-6.10 55.45% 10Y
-6.10 55.45% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.12 2.51%
ISIN
US52886X1072
Symbol
LXEO
Industry

Key metrics

Basic
Market capitalization
$264.6m
Enterprise Value
$132.8m
Net debt
positive
Cash
$132.9m
Shares outstanding
54.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.9
Financial Health
Equity Ratio
79.5%
Return on Equity
-83.9%
ROCE
-85.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-121.4m | $-88.7m
EBIT
$-123.4m | $-112.8m
Net Income
$-114.2m | $-145.4m
Free Cash Flow
$-95.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-49.9% | 14.7%
EBIT
-50.1% | -6.4%
Net Income
-47.7% | -48.4%
Free Cash Flow
-50.1%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-2.6
FCF per Share
$-1.8
Short interest
10.7%
Employees
61
Rev per Employee
$0.0
Show more

Is Lexeo Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Lexeo Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Lexeo Therapeutics forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Lexeo Therapeutics forecast:

Buy
93%
Hold
7%

Financial data from Lexeo Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 50 50
104% 104%
-
- Research and Development Expense 74 74
28% 28%
-
-121 -121
50% 50%
-
- Depreciation and Amortization 2.04 2.04
58% 58%
-
EBIT (Operating Income) EBIT -123 -123
50% 50%
-
Net Profit -114 -114
48% 48%
-

In millions USD.

Don't miss a Thing! We will send you all news about Lexeo Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lexeo Therapeutics Stock News

Neutral
GlobeNewsWire
10 days ago
Breakthrough Therapy designation granted for LX2006 based on interim data from Phase I/II trials demonstrating clinically meaningful improvements in cardiac and neurologic measures of Friedreich ataxia LX2006 selected for FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) program, created to facilitate CMC registrational readiness and support faster patient access...
Neutral
GlobeNewsWire
about 2 months ago
Breakthrough Therapy designation based on interim clinical data from Phase I/II trials showing clinically meaningful improvements in cardiac biomarkers and functional measures LX2006 also selected for FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) program, created to facilitate CMC registrational readiness and support faster patient access NEW YORK, July 07, 2...
Neutral
GlobeNewsWire
2 months ago
Up to $40 Million Private Equity Financing into a New Entity Addressing Cardiac Genetic Diseases that Existing AAV Platforms are Unable to Treat Lexeo Contributing Expertise and Know-How in Cardiac Genetic Medicines, Preclinical Intellectual Property, and Technology, in Combination with Novel Non-Viral RNA Delivery Platform Represents Pipeline Diversification and Advancement of Leading-Edge Car...
More Lexeo Therapeutics News

Company Profile

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.

Head office United States
CEO R. Townsend
Employees 61
Founded 2017
Website www.lexeotx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today